Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: What is the best approach?

Expert Review of Clinical Immunology

Volumn 9, Issue 10, 2013, Pages 937-947

  Caminati, Marco ^a   Dama, Annarita ^a   Schiappoli, Michele ^a   Senna, Gianenrico ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

adherence; effectiveness; efficacy; patient reported outcomes; safety; sublingual immunotherapy; tolerability

Indexed keywords

ALLERGEN; ALLERGOVIT; GRASS POLLEN VACCINE; ORALAIR GRASSES; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASTHMA; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR ITCHING; EDEMA; EYE TOXICITY; GLOSSODYNIA; HUMAN; HYPOTENSION; LIP ITCHING; LIP SWELLING; META ANALYSIS; MOUTH ULCER; NAUSEA; ORAL PRURITUS; ORAL SWELLING; PATIENT COMPLIANCE; PATIENT SATISFACTION; POLLEN ALLERGY; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINITIS; RISK REDUCTION; SENSITIZATION; STOMACH PAIN; SUBLINGUAL IMMUNOTHERAPY; SWELLING; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TASTE DISORDER; THROAT IRRITATION; TONGUE SWELLING; TONGUE ULCER; TREATMENT OUTCOME; URTICARIA; UVULAR EDEMA; VOMITING;

ADMINISTRATION, SUBLINGUAL; ADULT; ALLERGENS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; INHALATION EXPOSURE; MEDICATION ADHERENCE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 84886909068     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2013.837262     Document Type: Review

References (97)

1. Gupta R, Sheikh A, Strachan DP, Anderson HR. Time trends in allergic disorders in the UK. Thorax 62(1), 91-96 (2007).
2. Anandan C, Nurmatov U, van Schayck OC, Sheikh A. Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy 65(2), 152-167 (2010).
3. Maurer M, Zuberbier T. Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. Allergy 62(9), 1057-1063 (2007).
4. Bousquet J, Neukirch F, Bousquet PJ et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J. Allergy Clin. Immunol. 117(1), 158-162 (2006).
5. Wertz DA, Pollack M, Rodgers K, Bohn RL, Sacco P, Sullivan SD. Impact of asthma control on sleep, attendance at work, normal activities, and disease burden. Ann. Allergy Asthma Immunol. 105(2), 118-123 (2010).
6. Zuberbier T, Lötvall J. Allergies have a socio-economic impact. European academy of allergology and clinical immunology, annual meeting 2008. Allergy 63(Suppl. 84), 280-283 (2008).
7. Loddenkemper R. The first comprehensive survey on respiratory health in Europe. In: European Lung White Book. European Respiratory Society, Lausanne, Switzerland (2003).
8. Nasser S, Vestenbaek U, Beriot-Mathiot A, Poulsen PB. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy 63(12), 1624-1629 (2008).
9. Demoly P, Annunziata K, Gubba E, Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur. Respir. Rev. 21(123), 66-74 (2012).
10. Guilbert TW, Morgan WJ, Zeiger RS et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N. Engl. J. Med. 354(19), 1985-1997 (2006).
11. Allen DB. Effects of inhaled steroids on growth, bone metabolism, and adrenal function. Adv. Pediatr. 53, 101-110 (2006).
12. Layton D, Wilton L, Boshier A, Cornelius V, Harris S, Shakir SA. Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England. Drug Saf. 29(10), 897-909 (2006).
13. Burks AW, Calderon MA, Casale T et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J. Allergy Clin. Immunol. 131(5), 1288-1296 (2013).
14. Canonica GW, Bousquet J, Casale T et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 64(Suppl. 91), 1-59 (2009).
15. Bahceciler NN, Galip N. Comparing subcutaneous and sublingual immunotherapy: what do we know? Curr. Opin. Allergy Clin. Immunol. 12(6), 640-647 (2012).
16. Calderon MA, Demoly P, Gerth van Wijk R et al. EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin. Transl. Allergy 2(1), 20-27 (2012).
17. Hankin CS, Cox L, Bronstone A, Wang Z. Allergy immunotherapy: reduced health care costs in adults and children with allergic rhinitis.J. Allergy Clin. Immunol. 131(4), 1084-10891 (2013).
18. Walker SM, Durham SR, Till SJ et al. Immunotherapy for allergic rhinitis. Clin. Exp. Allergy 41(9) 1177-1200 (2011).
19. Sikora JM, Takersley MS. ACAAI Immunotherapy and Diagnostic Committee. Perception and practice of sublingual immunotherapy among practicing allergists in the United States. Ann. Allergy Asthma Immunol. 110(3) 194-197 (2013).
20. Cox L, Larenas-Linneman D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J. Allergy Clin. Immunol. 117(5), 1021-1035 (2006).
21. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J. Allergy Clin. Immunol. 102(4), 558-562 (1998)
22. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ318 (7183), 593-596 (1999).
23. Wilson DR, Lima MT, Durham SR Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60(1), 4-12 (2005)
24. Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 66(6), 740-752 (2011).
25. Calderon MA, Penagos A, Sheikh A, Canonica GW, Durham SR. Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analyses. Clin. Exp. Allerg. 41(9), 1263-1272 (2011).
26. Di Bona D, Plaia A, Scafidi V, Leto-Barone MS, Di Lorenzo G. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J. Allergy Clin. Immunol. 126(3), 558-566 (2010).
27. Lin SY, Erekosima N, Kim JM, Ramanathan M et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma. JAMA 309(12), 1278-1288 (2013).
28. Calamita Z, Saconato H, Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized clinical trials using the Cochrane Collaborative method. Allergy 61(10), 1162-1172 (2006).
29. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 64(11), 1570-1579 (2009).
30. Durham SR. Sublingual immunotherapy: what have we learnt from the "big trials". Curr. Opin. Allergy Clin. Immunol. 8(6), 577-584 (2008).
31. Malling HJ, Thomsen AB, Andersen JS. Heterogeneity can impair the results of Cochrane meta-analyses despite accordance with statistical guidelines. Allergy 63(12), 1643-1645 (2008).
32. Bachert C, Canonica GW, Bufe A. SIT efficacy depends on product not on route of application. Pediatr. Allergy Immunol. 23(4), 401-402 (2012).
33. Durham SR, Yang WH, Pedersen MR et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 117(4), 802-809 (2006).
34. Dahl R, Kapp A, Colombo G et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhino-conjunctivitis. J. Allergy Clin. Immunol. 118(2), 434-440 (2006).
35. Didier A, Malling HJ, Worm M et al. Optimal dose, efficacy and safety of once-daily sublingual immunotherapy with a 5 grass pollen tablet for seasonal allergic rhinitis. J. Allergy Clin. Immunol. 120(6) 1338-1345 (2007).
36. Worm M. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis. Eur. Ann. Allergy Clin. Immunol. 38(10) 335-360 (2006).
37. Nelson HS, Lehmann L, Blaiss MS. Efficacy and safety of timothy grass allergy immunotherapy tablets treatment in North American adults. J. Allergy Clin. Immunol. 127(1), 72-80 (2011).
38. Creticos PS, Maloney J, Bernstein DI et al. Randomized controlled trial of ragweed allergy immunotherapy tablet in North American and European adults. J. Allergy Clin. Immunol. 131(5), 1342-1349 (2013).
39. Wilson A, O'Byrne P, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am. J. Med. 116(5), 338-344 (2004).
40. Dahl R, Kapp A, Colombo G et al. Sublingual grass allergens tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J. Allergy Clin. Immunol. 121(2), 512-518 (2008).
41. Durham SR, Emminger W, Kappa A et al. SQ standardized sublingual immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J. Allergy Clin. Immunol. 129(3), 715-725 (2012).
42. Didier A, Worm M, Horak F, Sussman G et al. Sustained 3-years efficacy of pre and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass-induced rhinoconjunctivitis. J. Allergy Clin. Immunol. 128(3), 559-566 (2011).
43. Marogna M, Spadolini I, Massolo A, Canonica GWC, Passalacqua G. Long lasting effect according to the duration of SLIT: a 15 years prospective study. J. Allergy Clin. Immunol. 126(5), 969-975 (2010).
44. Tahamiler R, Saritzali G, Canakciouglu S. Long term efficacy of sublingual immunotherapy in patients with perennial rhinitis. Laryngoscope 117(6), 965-969 (2007).
45. Novembre E, Galli E, Landi F et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with rhinoconjunctivitis. J. Allergy Clin. Immunol. 114(4), 851-857 (2004).
46. Marogna M, Tomassetti D, Bernasconi A et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann. Allergy Asthma Immunol. 101(2), 206-211 (2008).
47. Malling HJ, Montagut A, Melac M et al. Efficacy and safety of 5 grass pollen sublingual immunotherapy tablets in patients with different clinical profile of allergic rhinoconjunctivitis. Clin. Exp. Allergy 39(3), 387-393 (2009).
48. Nelson H, Blaiss M, Nolte H et al. Efficacy and safety of the SQ standardized grass allergy immunotherapy tablet in mono and polysensitized patients. Allergy 68(2), 252-255 (2013).
49. Marogna M, Bruno ME, Massolo A, Falagiani P. Sublingual immunotherapy for allergic respiratory diseases in elderly patients: a retrospective study. Eur. Ann. Allergy Clin. Immunol. 40(1), 22-9 (2008).
50. Bozek A, Ignasiak B, Filipowska B, Jarzab J. House dust sublingual immunotherapy: a double blind placebo controlled study in elderly patients with allergic rhinitis. Clin. Exp. Allergy 43(2), 242-248 (2013).
51. Senna G, Calderon M, Makatsori M, Ridolo E, Passalacqua G. An evidence-based appraisal of the surrogate markers of efficacy of allergen immunotherapy. Curr. Opin. Allergy Clin. Immunol. 11(4), 375-380 (2011).
52. Bousquet PJ, Brozek J, Bachert C et al. The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper. Allergy 64(12), 1737-1745 (2009).
53. Casale TB, Canonica GW, Bousquet J et al. Recommendations for appropriate sublingual immunotherapy clinical trials. J. Allergy Clin. Immunol. 124(4), 666-670 (2009).
54. Passalacqua G, Baena-Cagnani CE, Bousquet J et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: Speaking the same language. J. Allergy Clin. Immunol. 132(1), 93-98 (2013).
55. Calderon MA, Simons FER, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 67(3), 302-311 (2012).
56. Calderon MA, Larenas D, Kleine-Tebbe J et al. European Academy of Allergy and Clinical Immunology task force on "dose-response relationship in allergen-specific immunotherapy". Allergy 66(10), 1345-1359 (2011).
57. Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 61(10), 1236-1237 (2006).
58. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 63(3), 374 (2008).
59. de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 64(6), 963-964 (2009).
60. Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA. Anaphylaxis to sublingual immunotherapy. Allergy 61(10), 1235 (2006).
61. Eifan AO, Keles S, Bahceciler NN, Barlan IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 62(5), 567-568 (2007).
62. Vovolis V, Kalogiros L, Mitsias D, Sifnaios E. Severe repeated anaphylactic reactions to sublingual immunotherapy. Allergol. Immunopathol. (Madr). 17(12), 263-267 (2012).
63. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: the World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J. Allergy Clin. Immunol. 125(3), 569-574 (2010).
64. Gidaro GB, Frati F, Sensi L, Marcucci F, Incorvaia C, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin. Exp. Allergy 35(5), 565-571 (2005).
65. Agostinis F, Tellarini L, Falagiani P, Canonica GW, Passalacqua G. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy 60(1), 133 (2005).
66. Di Rienzo V, Minelli M, Musarra A et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin. Exp. Allergy 35(5), 560-564 (2005).
67. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Post-marketing surveillance study on the safety of sublingual immunotherapy in children. Allergy 54(10), 1110-1113 (1999).
68. Lombardi C, Gargioni S, Melchiorre A, Passalacqua G. Safety of sublingual immunotherapy in adults: a post marketing surveillance study. Allergy 56(10), 889-892 (2001).
69. Pajno GB, Peroni DG, Vita D, Pietrobelli A, Parmiani S, Boner AL. Safety of Sublingual immunotherapy in children with asthma. Paediatr. Drugs 5(11), 777-781 (2003).
70. Fiocchi A, Pajno G, La Grutta S et al. Safety of SLI T in children aged 3 to 7 years. Ann. Allergy Asthma Immunol. 95(3), 254-258 (2005).
71. Drachenberg KJ, Urban E, Proll S, Woroniecki SR. Sublingual specific immunotherapy for adults and children: a post marketing survey. Allergol. Immunopathol. 32(2), 76-81 (2004).
72. Calderón MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J. Allergy Cin. Immunol. 127(1), 30-38 (2011).
73. Iglesias-Cadarso A, Hernández-Weigand P. Risk factors for systemic reactions to allergen immunotherapy. Curr. Opin. Allergy Clin. Immunol. 11(6), 579-585 (2011).
74. Wahn U, Tabar A, Kuna P et al. Efficacy and safety of 5 grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 123(1), 160-166 (2009).
75. Rodriguez F, Boquete M, Ibanez MD, de la Torre-Martinez F, Tabar AI. Once daily sublingual immunotherapy without updosing-a new treatment schedule. Int. Arch. Allergy Immunol. 140(4), 321-326 (2006).
76. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 61(2), 181-184 (2006).
77. Larsen H, Poulsen LK, Melac M, Combebias A, Andre C, Malling HJ. Safety and tolerability of grass pollen tablets in sublingual immunotherapy-a phase-1 study. Allergy 61(10), 1173-1176 (2006).
78. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol. Immunopathol. (Madr). 18(5), 277-284 (1990).
79. Passalacqua G, Canonica GW. Specific immunotherapy in asthma: efficacy and safety. Clin. Exp. Allergy 41(9), 1247-1255 2011).
80. Calderon MA, Cox L, Casale TB, Moingeon P, Demoly P. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J. Allergy Clin. Immunol. 129(4), 929-934 (2012).
81. Zuberbier T, Bachert C, Bousquet PJ et al GA2LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 65(12), 1525-1530 (2010).
82. Senna G, Ridolo E, Calderon M et al. Evidence of adherence to immunotherapy. Curr. Opin. Allergy Clin. Immunol. 9(6), 544-548 (2009).
83. Senna G, Lombardi C, Passalacqua G, Canonica GW. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturer's point of view. J. Allergy Clin. Immunol. 126(3), 668-669 (2010).
84. Baiardini I, Bousquet PJ, Brzoza Z et al. Global Allergy and Asthma European Network. Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper. Allergy 65(3), 290-295 (2010).
85. Patrick DL, Burke LB, Powers JH et al. Patient reported outcomes to support medical product labeling claims: FDA perspective. Value Health 10(Suppl. 2), S125-S137 (2007).
86. Guyatt GH, Oxman AD, Vist GE et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650), 924-926 (2008).
87. Braido F, Bousquet PJ, Brzoza Z et al. Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA(2)LEN taskforce position paper. Allergy 65(8), 959-968 (2010).
88. Serrano P, Justicia JL, Sánchez C et al. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study. Ann. Allergy Asthma Immunol. 102(3), 247-252 (2009).
89. Sieber J, Gross A, Shah-Hosseini K, Mösges R The RHINASTHMA GAV scores without SLIT, at the beginning and at the end of seasonal SLIT. Asian Pac. J. Allergy Immunol. 28(4), 232-236 (2010).
90. Ciprandi G, Cadario G, Valle C et al. Sublingual immunotherapy in polysensitized patients: effect on quality of life. J. Investig Allergol. Clin. Immunol. 20(4), 274-279 (2010).
91. Chang H, Han DH, Mo JH et al. Early compliance and efficacy of sublingual immunotherapy in patients with allergic rhinitis for house dust mites. Clin. Exp. Otorhinolaryngol. 2(3), 136-140 (2009).
92. Sade K, Berkun Y, Dolev Z, Shalit M, Kivity S. Knowledge and expectations of patients receiving aeroallergen immunotherapy. Ann. Allergy Asthma Immunol 91(5), 444-448 (2003).
93. Baiardini I, Puggioni F, Menoni S et al. Patient knowledge, perceptions, expectations and satisfaction on allergen-specific immunotherapy: a survey. Respir. Med. 107(3), 361-367 (2013).
94. Gutteling JJ, de Man RA, Busschbach JJ, Darlington AS. Quality of health care and patient satisfaction in liver disease: the development and preliminary results of the QUOTE-Liver questionnaire. BMC Gastroenterol. 20(8), 25-31 (2008).
95. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual. Life Outcomes 26(2), 12-25 (2004).
96. Clotet B, Carmena J, Pulido F, Luque I, Rodriguez-Alcantara F. COL30494 Cohort Study Members. Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients. HIV Clin. Trials 5(1), 33-39 (2004).
97. Justicia JL, Cardona V, Guardia P et al. Validation of the first treatment-specific questionnaire for the assessment of patient satisfaction with allergen-specific immunotherapy in allergic patients: The ESPIA questionnaire. J. Allergy Clin. Immunol. 131(6), 1539-1546 (2013).